Douglas Ried

Chair, Department of Clinical and Administrative Sciences
Ph.D., M.S.
Office: 2215
Phone: 305-760-7509
Hours: By Appointment


  • PhD, University of Minnesota, 1983
  • MS, University of Minnesota, 1982
  • BS, University of Washington, 1972 (Pharmacy)


Teaching Interests

Dr. Ried is an expert in the clinical effectiveness and adverse outcomes of mental health medications among geriatric patients, especially antipsychotics and antidepressants. One focus is on improved mortality after stroke with early treatment with antidepressants. Another area of interest is reducing adverse events and improving quality of life with second-generation antipsychotics. More recently, his primary focus is directed toward the assessment and evaluation of student learning and faculty teaching, especially of novel teaching methods such as online and active learning strategies, especially Team-based Learning (TBL).


Scholarly and Professional Interests

Dr. Ried’s practice and academic leadership roles have included his term president of the Academy of Pharmaceutical Research and Science and Board of Trustees of the American Pharmacists Association. He has been the recipient of numerous federal research grants and more than 100 peer-reviewed publications.  He also served as an associate editor and the editor-in-chief of the Journal of the American Pharmacists Association.  He has served on the editorial boards for the American Journal of Pharmaceutical Education, the Annals of Pharmacotherapy in the psychiatry panel and Research in


Social and Administrative Pharmacy. Dr. Ried has been the recipient of the Rufus Lyman Award for the best paper in the American Journal of Pharmaceutical Education on three occasions and he was the 2007-2008 Donald C. Brodie Academic Scholar-in-Residence. Dr. Ried is a fellow of the American Pharmacists Association Academy of Pharmaceutical Research and Science.  Dr. Ried has a long-standing scholarly interest in problem-based, team-based learning pedagogy and inter-professional educational initiatives.

Area of Specialty

  • Mental Health Patient Heath Reported Outcomes and Quality of Life
  • Pharmacoepidemiology
  • Geriatric Psychiatry
  • Curriculum Development
  • Curriculum and Programmatic Assessment


Selected Publications.

Ried LD, Hunter TS, Bos AJ, Ried DB. The Association Between Accreditation Era, NAPLEX Testing Changes and First-Time NAPLEX Pass Rates. Am J Pharm Edu. April 2023; 87(3): AJPE8994. DOI:

Ried LD, Ried DB. Predicting the 2016 US News & World Report Rankings Using a Reputation and Prestige Model. Curr Pharm Teach Learn. 2021; 13(2):91-101. doi: 10.1016/j.cptl.2020.09.011.

Ried LD, Ried DB. Elucidation of a Resource Reputation Model to Explain USNWR Ranking Using Path Analysis. Curr Pharm Teach Learn. 2020; Dec;12(12):1399-1409. doi: 10.1016/j.cptl.2020.07.009.

Ried LD. Length of advanced pharmacy practice experience and first-time NAPLEX pass rate of US pharmacy programs. Curr Pharm Teach Learn. 2020 Jan;12(1):14-19. doi: 10.1016/j.cptl.2019.10.009.

Ried LD, Douglas CA. Towards an Operational Definition of Pharmacy Clinical Competency.  Am J Pharm Educ. 2015; 79(4): Article 54. Rufus A Lyman Award, American Association of Colleges of Pharmacy – 2016.

Ried LD. A Model for Curricular Quality Assessment and Improvement.  Am J Pharm Educ.  2011; 75(10): Article 196.

Wilson DL, Ried LD. Identifying Iatrogenic Depression Using Confirmatory Factor Analysis of the Center for Epidemiologic Studies Depression Scale (CES-D) in Patients Prescribed a Verapamil-SR-led or Atenolol-led Hypertension Treatment Strategy. Res Soc Admin Pharm. 2012; 8(4):309-320.

Ried LD, Jia H, Feng H, Cameon R, Wang X, Tueth MJ, Wu S. Does Prestroke Depression and Treatment Impact Poststroke Mortality? Ann Pharmacother. 2011; 45(7-8):888-897.

Ried LD. Evaluation of a Distance Education Statistics Course. Am J Pharm Educ. 2010; 74(9): Article 172.

Ried LD, Brumback B, Bengtson MA, Garman KP, Hsu C, McConkey JR.  Glucose Dysregulation Among Veterans Living with Schizophrenia-Related Disorders After Switching Second-Generation Antipsychotics.  J Am Pharm Assoc. 2009; 49:223-31.